Cleveland

MediView Announces First Clinical Use of FDA-Cleared XR90 Augmented Reality-Based Visualization and Navigation Platform

Retrieved on: 
Thursday, November 9, 2023

CLEVELAND, Nov. 9, 2023 /PRNewswire/ -- MediView XR, Inc., a leading clinical augmented reality (AR) med-tech company, announced today the first inpatient utilization of its XR90 AR-based surgical visualization and navigation system since its 510(k) clearance from the U.S. Food and Drug Administration.

Key Points: 
  • CLEVELAND, Nov. 9, 2023 /PRNewswire/ -- MediView XR, Inc., a leading clinical augmented reality (AR) med-tech company, announced today the first inpatient utilization of its XR90 AR-based surgical visualization and navigation system since its 510(k) clearance from the U.S. Food and Drug Administration.
  • The system is intended to be used adjunctively for minimally invasive ultrasound and CT guided needle-based procedures for soft tissue and bone.
  • "We are pleased at the successful utilization of our holographic visualization and navigation system," said Mina Fahim, President and CEO of MediView.
  • Dr. Pua then used the holographic needle tracking feature of the XR90 system to plan his approach before confirming on standard of care.

HeartBeam Announces Expansion of Its Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
  • He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
  • “We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies.

Allegheny Health Network Advances Virtual Critical Care Service with Launch of New, In-House 'TeleICU' Program

Retrieved on: 
Wednesday, November 8, 2023

PITTSBURGH, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) and Highmark Health announced today the launch of a new virtual intensive care solution which combines innovative telehealth technology and the clinical expertise of AHN intensivists for centralized, 24/7 monitoring and management of critically ill patients at six of the network's hospitals across western Pennsylvania.

Key Points: 
  • This program proved to be a valuable resource for the network and patients throughout the COVID-19 pandemic, supporting response and care planning.
  • "With the launch of TeleICU, we are pleased to transition our virtual ICU service fully in-house, extending the expertise of our own intensivists across the network and further enhancing the quality of care that we provide."
  • The TeleICU command center is located at 4 Allegheny Center (4AC) on Pittsburgh's Northside nearby AHN Allegheny General Hospital.
  • "The collaborative launch of TeleICU with AHN as the pacesetter marks yet another important milestone along our journey to transform health care."

Bridgestone Partners with Play Like a Girl!® to Launch Girls Flag Football and STEM Initiatives with Five Professional Football Teams

Retrieved on: 
Wednesday, November 8, 2023

® are teaming up with the Cleveland Browns, Dallas Cowboys, Los Angeles Rams, New England Patriots and Tennessee Titans to empower girls through sports and STEM activities.

Key Points: 
  • ® are teaming up with the Cleveland Browns, Dallas Cowboys, Los Angeles Rams, New England Patriots and Tennessee Titans to empower girls through sports and STEM activities.
  • Bridgestone is donating $100,000 to Play Like a Girl!® to help girls across the country gain more equitable access to opportunities in sports and education.
  • Together, Bridgestone, PLAG and participating teams have hosted interactive girls flag football Field Days across the past month featuring drills with professional football players, a hands-on STEM activity, and a panel discussion featuring female leaders from each organization.
  • Bridgestone will further support each girls flag football market in different ways, including team transportation funding, development of a digital educational portal, equipment donation and more.

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023

RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending September 30, 2023, and provided a corporate update.

Key Points: 
  • ET –
    RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending September 30, 2023, and provided a corporate update.
  • Research and Development (R&D) expenses were $22.5 million for the quarter ended September 30, 2023, compared to $6.1 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) expenses were $3.8 million for the quarter ended September 30, 2023, compared to $1.4 million for the quarter ended September 30, 2022.
  • Net loss was $22.8 million for the quarter ended September 30, 2023, compared to $6.7 million for the quarter ended September 30, 2022.

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Retrieved on: 
Wednesday, November 1, 2023

"Recurrent pericarditis is a debilitating inflammatory heart disease associated with symptoms that adversely affect quality of life and physical activity.

Key Points: 
  • "Recurrent pericarditis is a debilitating inflammatory heart disease associated with symptoms that adversely affect quality of life and physical activity.
  • MAvERIC-Pilot is enrolling 25 patients at medical research centers in the United States that specialize in pericarditis care.
  • The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis.
  • Pre-clinical data adding to the strong scientific basis for investigating CardiolRx™ clinically in recurrent pericarditis were presented at the American Heart Association Scientific Sessions 2022.

AAPA, PA Foundation, Cleveland Clinic, and Davos Alzheimer’s Collaborative Release Early Cognitive Assessment Toolkit

Retrieved on: 
Wednesday, November 1, 2023

ALEXANDRIA, VA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA), PA Foundation (PAF), Cleveland Clinic , and Davos Alzheimer’s Collaborative (DAC) today publicly released an early cognitive assessment toolkit .

Key Points: 
  • ALEXANDRIA, VA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA), PA Foundation (PAF), Cleveland Clinic , and Davos Alzheimer’s Collaborative (DAC) today publicly released an early cognitive assessment toolkit .
  • The toolkit can be accessed by both providers and patients with the aim of improving clinical workflow and increasing rates of cognitive assessment in primary care settings.
  • During the testing period, feedback was collected from providers to ensure the toolkit could be easily transferred and used in practice.
  • “The development of this cognitive assessment toolkit allows providers to readily address cognitive concerns in older adults and implement best practices for mild cognitive impairment and dementia.

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD

Retrieved on: 
Tuesday, October 31, 2023

The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company’s lead therapeutic candidate, efzofitimod, compared to placebo in patients with systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease (ILD).

Key Points: 
  • The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company’s lead therapeutic candidate, efzofitimod, compared to placebo in patients with systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease (ILD).
  • Efzofitimod has been granted U.S. Food and Drug Administration (FDA) and European Union orphan drug and U.S. FDA Fast Track designations for SSc.
  • “We are very pleased to begin patient dosing in EFZO-CONNECT™, which is our second clinical study for efzofitimod in ILD,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
  • aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD.

Italy-USA: Business Care International Award ceremony in NY, special award to Marco Durante

Retrieved on: 
Friday, October 27, 2023

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The Consulate General of Italy in New York hosted the awards ceremony for the 6th edition of the 'Business Care International Award' on Thursday.

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The Consulate General of Italy in New York hosted the awards ceremony for the 6th edition of the 'Business Care International Award' on Thursday.
  • The recognition, as explained by the creator of the award and president of Business Care Communication, Massimo Veccia, is awarded every year to the personalities representing the "best contemporary Italian spirit."
  • New to this year's edition was the Special Award to the 'Best Italian Entrepreneur in the United States of America 2023-2024', awarded to Marco Maria Durante, publisher of the LaPresse news agency.
  • We have made investments in this country," commented Durante during the ceremony.

Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session

Retrieved on: 
Thursday, November 2, 2023

Data were aggregated from DETOUR1 and DETOUR2, both of which were prospective, single-arm, multi-center, international studies designed to evaluate the DETOUR System.

Key Points: 
  • Data were aggregated from DETOUR1 and DETOUR2, both of which were prospective, single-arm, multi-center, international studies designed to evaluate the DETOUR System.
  • For the pooled analysis, primary patency was defined as freedom from target vessel revascularization (TVR).
  • “We are pleased to present the combined results of the DETOUR1 and DETOUR2 Studies.
  • Safety and Performance of percutaneous Transmural Femoropopliteal Bypass with the DETOUR System: Pooled analysis of DETOUR1 and DETOUR2.